Ashish Sarraju, M.D.

Stories

One-time CRISPR therapy keeps cholesterol lower for a full year in early trial

Presented Phase 1b CTX310 results at AHA Scientific Sessions 2026

CRISPR Therapeutics' CTX310 cut triglycerides by 63% and ANGPTL3 by 65% a month after one infusion in 10 patients with severely high triglycerides, the company reported Nov. 9 at the American Heart Association meeting. The Phase 1b results follow a Phase 1a trial in which the same one-time treatment kept LDL cholesterol about 52% lower for a year.

Updated 2 days ago